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This project addressed burn wound healing through controlled release of the antibacterial drug 
mafenide encapsulated by a copolyster into 3D printed scaffolds. Scaffolds were printed at 25oC 
and 0.77-1 bar in a cross-hatch pattern with uniform thickness, distance between parallel layers, 
and diameter then photo-crosslinked. The number of scaffolds available for testing was limited by 
the amount of polymer that could be synthesized. A high-performance liquid chromatography 
method was developed specifically for this experiment and used to determine daily release of 
mafenide from the scaffold into a 2-mL phosphate buffer solution. During the first 24 hours a large 
burst release of 299.9 g or 7.9% of the initial drug amount was observed for the 2-layer scaffolds 
and 403.1 g or 8.7% of its initial drug amount for the 3-layer scaffolds. Within 120 hours, the 
release rate had dropped to less than 100 g per day for both scaffold types. The cumulative 
average release for the 2-layer and 3-layer scaffolds was determined to be 1449.0 g (38.8% of 
the initial total) and 1469.5 g (31.8% of the initial total) respectively. The results suggest that 
these scaffolds have the potential to become a viable treatment option in the future. 
  
Executive Summary 
 During the burn wound healing process, bacterial infection is a significant issue that can 
complicate treatment and patient recovery. This project aimed to address burn wound healing and 
bacterial contamination through controlled release of antibacterial drugs encapsulated by a 
polymer into 3D printed scaffolds. Mafenide, typically as mafenide acetate, is one such drug used 
to prevent infection in burn wounds. The drug is commonly applied as a topical cream but induces 
some negative side effects such as pain on contact and the presence of residue on the skin (Falcone 
et. al.). Because of these side effects, the use of 3D printed scaffolds containing mafenide may be 
a better treatment method, as it also increases the potential to optimize recovery and reduce costs. 
 Scaffolds of two and three layers containing 10% mafenide by weight and a phenylalanine-
coumarin copolyester were printed. A phosphate buffer solution and incubator were used to 
simulate conditions within the body. Daily release of mafenide was quantified by collecting 
supernatant samples and analyzing them using high performance liquid chromatography (HPLC) 
in order to determine if the drug could be delivered in suitable quantities to provide potentially 
viable treatment.  
 The experiment ran for 384 hours, and it was determined that mafenide could be released 
in quantifiable amounts. The average amount of mafenide released daily and the cumulative 
average amount of mafenide released over the entire period were determined for the 2-layer and 
3-layer scaffolds. An initial burst release of mafenide was observed in this experiment. During the 
first 24 hours, the 2-layer scaffolds released roughly 299.9 g or 7.9% of the initial total drug on 
average whereas the 3-layer scaffold released 403.1 g or 8.7% of the initial total drug. By 120 
hours, both the 2-layer and 3-layer scaffolds were releasing less than 100 g per day. Despite 
initially releasing different amounts of drug, the 2-layer and 3-layer scaffolds delivered almost 
identical total amounts of mafenide during the 384-hour period. The cumulative average release 
for the 2-layer scaffolds was determined to be 1449.0 g while the cumulative release amount for 
the 3-layer scaffold was 1469.5 g. These release amounts correspond to roughly 38.8% of the 
initial total mafenide for the 2-layer scaffolds and 31.8% of the initial total mafenide for the 3-
layer scaffolds.  
 From these results it can be concluded that mafenide can successfully be encapsulated by 
a polymer into a matrix that can be used to 3D print scaffolds for drug delivery. The release data 
shows that mafenide may be released from these structures for an extended period of time. HPLC 
analysis of irradiated mafenide indicates that the drug does not break down as a result of exposure 
to UV light. As a result, the photo-crosslinking process is not harmful to the mafenide and can be 
implemented in order to stabilize the scaffolds. The initial surge release of mafenide from the 
scaffold suggests that the polymer-drug matrix contained greater amounts of drug at the surface. 
Because small percentages of the initial total amount of mafenide can be released even after a 
prolonged duration, this treatment method may be viable if the initial amount of mafenide present 
in the scaffold enables the appropriate dosage to be delivered.   
 This work explores an alternative treatment method to those commonly used for mafenide 
that, if successful, may help patients avoid negative side effects while still receiving the necessary 
treatment for their burn wounds. This research provides the foundation for additional investigation 
into mafenide encapsulation and delivery. Because the results show that this method of drug 
delivery may be viable for mafenide, it opens the possibility to explore other antibacterial drugs 
for burn wounds using this process.  
 Future work on this topic should be done to investigate the efficacy of this treatment option 
for mafenide. In future experimentation, obtaining multiple scaffolds with more uniform weights 
for each number of layers being tested should be prioritized to ensure greater accuracy in the 
results. The goal of future work should be to modify different experimental variables in order to 
achieve a consistent daily delivery of the drug. Changes can be made to mafenide concentration, 
scaffold geometry, scaffold dimensions, number of scaffold layers, and encapsulating polymer in 
order to achieve this goal.  
 




 This project sought to address burn-wound healing and principles of tissue engineering via 
the controlled release of antibacterial therapeutics incorporated into 3D printed scaffolds. Burns 
are typically acute injuries that fully heal within a short period of time with limited scarring (Nun 
et. al.). More severe burns, such as third-degree burns, may take significantly longer time to heal 
while requiring skin grafts and other treatment. During the wound healing process, it is essential 
that bacterial contamination be eliminated or minimized in order to prevent infection of the injured 
tissue. Topical creams are typically used to address this issue, but due to possible negative side 
effects and the need to continually apply the ointment to the affected area, the use of 3D printed 
scaffolds containing antibacterial drugs may be a more favorable alternative. This method of 
controlled release offers the potential to optimize drug concentration, reduce treatment cost, and 
improve patient compliance (Nun et al.). 
 The focus of this project was on the bacteriostatic agent mafenide. This research builds off 
previous work completed in Dr. Joy’s laboratory related to quantifying release rates for drugs 
incorporated into 3D printed scaffolds, e.g., the anti-inflammatory drug dexamethasone. Scaffolds 
containing 10% mafenide by weight and a phenylalanine-coumarin copolyester were printed with 
either 2 or 3 layers. The scaffolds were placed in a phosphate buffer solution (PBS) which was 
collected and replaced with fresh solution every 24 hours. Drug delivery was quantified using high 
performance liquid chromatography (HPLC). Detailed experimental methods, results, and analysis 





 Mafenide, typically as mafenide acetate, is a sulfa antibiotic drug that is often delivered in 
a topical cream or aqueous solution (Falcone et. al.). The drug is highly soluble in water, has low 
affinity for plasma proteins, and inhibits bacterial growth with minimal to no onset of resistance 
(Falcone et. al.). As mafenide acetate the drug has a molecular wight of 246.3 g/mol and is soluble 
in water up to a level of 250 mg/mL (Elsner and Zilberman). Mafenide is often used to inhibit 
bacterial growth in burn wounds to decrease the risk of infection and promote healing. Elsner and 
Zilberman note that the drug is effective on second and even third-degree burns. According to 
Falcone et. al., mafenide has been successful in reducing infections and increasing the survivability 
of burn victims. Despite its efficacy, negative side effects of topical mafenide creams exist, such 
as pain on application and the formation of a gummy layer upon drying that must be removed with 
water (Falcone et. al.). Other treatment options utilizing mafenide may be more desirable to avoid 
these adverse effects.  
 Falcone et. al. investigated wound dressings containing mafenide and determined that 
continual saturation of the dressing is the most effective method of ensuring optimal drug delivery. 
Elsner and Zilberman also studied mafenide wound dressings, among others, by creating a 
structure containing a polyglyconate core and a porous poly(DL-lactic-co-glycolic acid) shell then 
adding the drug. They found that desirable release profiles for mafenide could be obtained from 
these structures and that factors could be controlled to lower the burst release that is common in 
these scenarios (Elsner and Zilberman). Previous work in Dr. Joy’s laboratory, such as the 
experiment described in Jain et. al. in which dexamethasone was used, has shown that scaffolds 
containing drugs encapsulated in a polymer can be 3D printed and used as means of drug delivery. 
The experimental methods described below were largely based off the design set forth in Jain et. 
al. with some modifications due to the difference in drugs being used.      
 
Experimental Methods 
 Experimentation began with the synthesis of the phenylalanine monomer. A stir bar and 3-
phenylpropanoic acid were added to a round bottom flask. An addition funnel was attached and 2 
cycles of vacuum and nitrogen purging were done to the flask. Dry methanol was added to the 
flask which was placed in an ice bath to control the temperature and reaction. After 5 minutes of 
stirring, thionyl chloride was added dropwise to the flask. The contents were allowed to react for 
24 hours, then sodium sulfate was added to control the pH of the mixture. Water containing a 
couple drops of hydrogen chloride was added to dissolve the sodium sulfate. The mixture was 
dried, and the mass of the intermediate product of 3-phenylpropionate was obtained. The final 
monomer product was obtained by adding diethanolamine to the intermediate product and 
allowing the two to react.  
 Small amounts of unreacted materials and intermediate product remained present in the 
mixture, meaning separation of the desired phenylalanine polyester monomer was necessary. The 
contents of the mixture were run through a column packed with a large layer of silica as the 
stationary phase and a smaller layer of sand on top. The sand ensured the mobile phase would be 
uniform when entering the silica. Because the chemicals move through the stationary phase at 
different rates, separation of the contents could be achieved. Thin layer chromatography (TLC) 
was performed as liquid drained from the column to determine the contents of the exiting fluid. 
When only the desired product showed up in the TLC tests, the exiting fluid was collected. The 
collected product was placed in a rotovap to provide separation. 
 The phenylalanine monomer was copolymerized with a long-chain coumarin polyester 
containing a seven-carbon tail. The two monomers were added to a flask with succinic acid and 
1,4-Dimethylpyridinium p-toluenesulfonate (DPTS). Three cycles of vacuum and nitrogen were 
done, then dichloromethane (DCM) was added. After the contents dissolved, N,N'-
Diisopropylcarbodiimide (DIC) was added dropwise to the flask, and the reaction was allowed to 
proceed for 48 hours. The solution was filtered with DCM and placed in a rotovap. The contents 
were then placed in dialysis bags and left in methanol overnight. The polymer was precipitated 
using methanol then dried via a centrifuge and then vacuum.  
   Mafenide and polymer were combined by dissolution to create a mixture containing 10% 
drug. Due to solubility issues, the mixture was precipitated in ether and dried using high vacuum 
overnight. Drug-polymer scaffolds of two and three layers with a diameter of 12 mm were created 
using a 3D printer set to 25oC and within a pump pressure range of 0.77 to 1 bar. The scaffolds 
were printed in a cross-hatch pattern with uniform dimensions, including layer thickness and 
distance between parallel layers. After printing, the scaffolds were photo-crosslinked using UV 
light at an intensity range of 87-95 mW/cm2. The 2-layer scaffolds were exposed to the UV for 
300 seconds on each face. The 3-layer scaffolds were exposed to the UV for 300 seconds on each 
face and then an additional 300 seconds on the top side. Four 2-layer scaffolds and one 3-layer 
scaffold remained intact for experimentation after printing and crosslinking. A control group of 
scaffolds containing only polymer were also printed. The weight of each scaffold was obtained as 
well as the weight of each 20 mL vial used to hold each scaffold for the duration of the experiment.   
 A phosphate buffer solution (PBS) with a pH of 2.5 was used to facilitate the release of 
mafenide from the 3D printed scaffolds. The solution was prepared using ultrapure water, sodium 
dihydrogen phosphate monohydrate, and 85% phosphoric acid. Scaffolds were submerged in 2 mL 
of PBS and then placed in an incubator set to 37oC and 60 RPM. The supernatant was collected 
every 24 hours and replaced with 2 mL of fresh PBS. For the control scaffolds, this was done 
weekly instead.  
 Samples were analyzed using high-performance liquid chromatography (HPLC). A method 
was prepared specifically for this experiment. The temperature of the column was controlled at 
20oC, and a wavelength of 235 nm was chosen for the UV lamp. The mobile phase consisted of 
PBS and acetonitrile flowing at 1 mL/min for 10 minutes. From 0 to 3 minutes, the mixture 
consisted of 90% PBS (10% acetonitrile). From 3 minutes to 6 minutes the PBS content dropped 
to 75%. From 6 minutes to 9 minutes the PBS concentration dropped again to 60%. For the final 
minute, the mixture was set to 45% PBS. A calibration curve was prepared by using this HPLC 
method to obtain the peak area of various known concentrations of mafenide in PBS. The 
concentration of each sample was then determined from this calibration curve. The amount of drug 
released could then be determined. Additionally, in order to monitor drug sensitivity and 
degradation resulting from UV light, a 1 mg sample of mafenide was irradiated with 87-95 
mW/cm2 for two cycles of 300 seconds then placed in 1 mL PBS and analyzed using this HPLC 
method.    
 After the duration of the experiment, the scaffolds were dried using liquid nitrogen then 
left under vacuum overnight. The mass of the vial and scaffold together was measured after 
removing solid residue that remained in the vials. The final mass of the scaffold could be 
determined by subtracting the previously obtained vial weight from the combined weight with the 




 The number of scaffolds that could be printed was limited by the amount of polymer that 
could be synthesized. Because of this, there was insufficient material to obtain multiple 3-layer 
scaffolds. Since average values were reported for the amount of mafenide released, this may have 
affected the results for the 3-layer scaffold. Additionally, the first 2-layer scaffold contained 
significantly more mass than the other 2-layer scaffolds as well as the 3-layer scaffold. Because it 
was printed first, excess material may have accumulated in the 3D printing needle head, leading 
to its larger size. This outlier may have affected the release results since so few scaffolds could be 
tested. In future experiments, the initial mass of each scaffold and the amount of drug present 
should be more uniform to obtain a more representative average.  
 The polymer degradation study provided evidence that there is no interference with the 
mafenide peak, indicating accurate results for mafenide release were obtained from the HPLC 
testing. Also, the analysis of the irradiated mafenide indicates that the drug did not denature as a 
result of the crosslinking method performed in this experiment. This means that the drug would 
still be viable after incorporation into the scaffold and has the potential to provide treatment in this 
form.  
 The release data shows that mafenide can successfully be encapsulated by a polymer into 
a 3D printed scaffold which may then be used to provide transdermal or subdermal delivery of the 
drug. The trends observed in the release data regarding an initial burst release of a large amount of 
drug followed by a sharp drop off in daily release matches closely with other experiments of a 
similar nature as revealed with the dexamethasone encapsulations described in Jain et. al. This is 
the result of large amounts of drug being present at the surface of the 3D printed matrix instead of 
being uniformly dispersed (Jain et. al.). Scanning electron microscope (SEM) imaging can be used 
in the future to further analyze the scaffolds and the pores within to determine whether or not this 
was the case.  
 The similarity between the cumulative amount of mafenide released for the 2-layer and 3-
layer scaffolds is surprising. Because more drug was present on average in the 3-layer scaffold, it 
was expected to have a higher cumulative average release. This disparity can also be observed with 
the cumulative average percentage of drug released, since the 3-layer scaffold released roughly 
7% less of the initial amount of drug than the 2-layer scaffolds did after 384 hours. The 
aforementioned issues regarding the limited number of scaffolds available conflated these 
discrepancies between expected and observed results, since only one 3-layer scaffold could be 
tested.  
 Additional work on this topic should be done to investigate the viability of this treatment 
option for mafenide. In future experimentation, obtaining enough polymer to print multiple 
scaffolds for each number of layers being tested is essential to obtain representative results. 
Developing a method to achieve a consistent daily delivery of the drug should be the goal of future 
work on this topic. Changes to mafenide concentration, scaffold geometry, scaffold dimensions, 
number of scaffold layers, and encapsulating polymer are all variables with the potential to be 




T. Jain, D. Saylor, C. Piard, Q. Liu, V. Patel, R. Kaushal, J.-W. Choi, J. Fisher, I. Isaveya, A. Joy  
 “Effect of Dexamethasone on Room Temperature Three-Dimensional Printing, 
 Rheology, and Degradation of a Low Modulus Polyester for Soft Tissue Engineering.” 
 ACS Biomaterials Science & Engineering, vol. 5, no. 2, 2019, pp. 846-858. 
N. Nun, M. Cruz, T. Jain, Y-M. Tseng, J. Menefee, S. Jatana, P.S. Patil, N.D. Leipzig, C.  
 McDonald, E. Maytin, A. Joy. “Thread size and polymer composition of 3D printed and  
 electrospun wound dressings affect wound healing outcomes in an excisional wound rat  
 model.” Biomacromolecules, vol. 21, 2020 pp. 4030-4042. 
P. Falcone, H. Harrison, G. Sowemimo, G. Reading. “Mafenide Acetate Concentrations and  
 Bacteriostasis in Experimental Burn Wounds Treated with a Three-Layered Laminated  
 Mafenide-Saline Dressing,” Annals of Plastic Surgery vol. 5, no. 4, 1980 
J. Elsner, M. Zilberman. “Antibiotic-eluting bioresorbable composite fibers for wound healing  
 applications: Microstructure, drug delivery and mechanical properties.” Acta  
 Biomaterialia vol. 5, 2009, pp. 2872-2883 
 
